<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786340</url>
  </required_header>
  <id_info>
    <org_study_id>WST-PZP-003</org_study_id>
    <secondary_id>5R44DK104512</secondary_id>
    <nct_id>NCT04786340</nct_id>
  </id_info>
  <brief_title>A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel, 12-week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetes Mellitus Patients With Painful Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WinSanTor, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>WinSanTor, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects&#xD;
      with Type II Diabetes and painful peripheral neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed with 4 periods: screening, baseline/day 0, outpatient treatment, and&#xD;
      safety follow-up. Site visits take place At -30 days, -7 days, Day 0, Week 3 (phone&#xD;
      assessment), 6, 9 (phone assessment) and 12/end of study [EOS]. There is also a Week 14 phone&#xD;
      call for a safety review with the subject. The purpose of this early phase 2 trial is to&#xD;
      evaluate the overall safety and tolerability of both the active topical solution and the&#xD;
      placebo also called the 'vehicle' formulated as a topical solution that penetrates the skin&#xD;
      of the lower legs and tops of the feet. There are also secondary and exploratory objectives&#xD;
      to determine if this active has efficacy properties during the 12-week treatment period as&#xD;
      hypothesized. Even though pirenzepine is approved and used for another indication&#xD;
      systemically, the sponsor believes the active in a topical solution to be effective in&#xD;
      treating painful peripheral neuropathy commonly found in diabetic patients.&#xD;
&#xD;
      There are both objective and subjective tests being introduced in this trial due to the&#xD;
      unique nature of the study, and lack of defined and standardized efficacy parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">May 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 ratio masking with 36 subjects assigned to active treatment, 4% WST-057 topical solution and, 18 subjects randomly assigned to a non-active matching placebo solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each subject will be randomized by an independent web-based source called IWRS. When a subject is randomized, the IWRS will assign a randomization number for each subject, corresponding to a specific treatment code. The randomization number will be automatically input into the eCRF by the system. The corresponding treatment code will only be accessible to the unblinded personnel.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events as assessed by hematology and clinical pathology blood tests</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be assessed by observing changes in patients' blood tests when compared to normal lab values/ranges after once daily dosing of 1 dose level of WST-057 solution or placebo. The number of participants with treatment-related adverse events as assessed by CTCAEv4.0 will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events as assessed by vital signs (blood pressure (diastolic and systolic mmHg), heart rate (beats per minute), respiratory rate (breaths per minute).</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be assessed by observing changes in patients' blood tests when compared to normal lab values/ranges after once daily dosing of 1 dose level of WST-057 solution or placebo. The number of participants with treatment-related adverse events as assessed by CTCAEv4.0 will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events as assessed by ECG (measuring p wave, QRS complex, QT interval)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be assessed by observing changes in patients' blood tests when compared to normal lab values/ranges after once daily dosing of 1 dose level of WST-057 solution or placebo. The number of participants with treatment-related adverse events as assessed by CTCAEv4.0 will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events as assessed by dermal assessment (Draize score 0.0-4.0) score of skin erythema, edema pruritus and dryness score) of the dosing area</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety will be assessed by observing changes in patients' blood tests when compared to normal lab values/ranges after once daily dosing of 1 dose level of WST-057 solution or placebo. The number of participants with treatment-related adverse events as assessed by CTCAEv4.0 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogues Score (VAS) for pain assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Scores are based on self-reported measures of symptoms that are recorded with a single mark placed at one point along a horizontal line 100 mm in length that represents a continuum between the two ends of the scale-&quot;no pain&quot; on the left end of the scale and the &quot;worst imaginable pain&quot; on the right end of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utah Early Neuropathy Score (UENS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Utah Early Neuropathy Scale (UENS) is a simple, rapid, and reproducible test targeted to detect early sensory peripheral neuropathy. It includes motor examination, pin sensation, allodynia, hyperesthesia, large-fiber sensation, and deep tendon reflexes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Patients' Global Impression of Change (PGIC) scale will be used to assess patients' perception of changes following treatment (i.e., &quot;feeling better&quot; or &quot;feeling worse&quot;). The PGIC is a 7-point verbal scale. The PGIC is commonly used in clinical studies assessing pain relief following treatment, due to its ease of administration and scoring and because it is a generic scale applicable to a wide variety of conditions and treatments including diabetic peripheral neuropathy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intraepidermal Nerve Fiber Density (IENFD) of the dosing area</measure>
    <time_frame>12 weeks</time_frame>
    <description>Skin Biopsies and quantification of IENF density (IENFD): This measurement will provide the other co-secondary outcome measures for the study so that effects on both patient function and nerve structure are assessed. IENFD is the gold standard for measuring small fiber neuropathy</description>
  </other_outcome>
  <other_outcome>
    <measure>Norfolk Quality of Life for Diabetic Peripheral Neuropathy -Physical Large Fiber Function Subset Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) tool is a validated, 35-item, self-administered questionnaire that measures the relationship between symptoms of diabetic neuropathy and Quality of Life (QoL). It is subdivided in 5 domains that include measures of somatic nerve function (small and large fibers), symptoms, autonomic nerve function and activities of daily living (ADLs)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo: 4 mL of matching placebo topical solution.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution</intervention_name>
    <description>WST-057 is pirenzepine a free base monohydrate. It is formulated into a topical solution (also the placebo); the solution is clear and viscosity is low enough for dispensing through a pump; each pump dispenses approximately 1 mL; patients are to use 4 mL every day approximately the same time of day;</description>
    <arm_group_label>Placebo: 4 mL of matching placebo topical solution.</arm_group_label>
    <arm_group_label>WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution</arm_group_label>
    <other_name>Placebo: 4 mL of matching placebo topical solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible to participate in&#xD;
        the study:&#xD;
&#xD;
          1. Diagnosis of T2DM (as defined by the 2016 American Diabetes Association guidelines).&#xD;
&#xD;
          2. Male and female patients in the age range of 30 to 75 years (inclusive).&#xD;
&#xD;
          3. Diagnosis of diabetic neuropathy (as defined by the Toronto Consensus Guidelines) of&#xD;
             at least 12 months duration in the lower extremities.&#xD;
&#xD;
          4. Provide written informed consent prior to entering the study or undergoing any study&#xD;
             procedures.&#xD;
&#xD;
          5. Females should be either not of childbearing potential as a result of surgery or&#xD;
             menopause (1 year after onset), or of childbearing potential and must be practicing a&#xD;
             highly effective medically acceptable method of contraception, including abstinence;&#xD;
             hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring,&#xD;
             injectables, and implants); intrauterine device or intrauterine system; or vasectomy&#xD;
             (partner), for at least 1 month before the screening visit and for 1 month after the&#xD;
             end of the study. If access or use of a highly effective medically acceptable method&#xD;
             of contraception is not achievable, then a combination of barrier methods (e.g., male&#xD;
             condom, female condom, cervical cap, diaphragm, contraceptive sponge) is acceptable.&#xD;
             Eligible female subjects must also have a negative serum beta-human chorionic&#xD;
             gonadotropin at the screening visit.&#xD;
&#xD;
          6. Males must use an acceptable form of contraception (e.g., male condom with diaphragm,&#xD;
             male condom with cervical cap, or male condom in association with spermicide).&#xD;
&#xD;
          7. Prior 24 hrs VAS for pain and/or altered sensations on lower extremities &gt; 30 mm (0 mm&#xD;
             = no pain-100 mm = very severe pain) at screening.&#xD;
&#xD;
          8. Participating subjects must be reliable, willing, and able to cooperate with all study&#xD;
             procedures, including the following:&#xD;
&#xD;
               -  Return for study visits on the required dates&#xD;
&#xD;
               -  Be physically able to inspect calves, tops of ankles, and soles of feet for&#xD;
                  wounds, infections, or other anomalies, and be able to self-administer the&#xD;
                  investigational drug to calves and top surface of feet.&#xD;
&#xD;
               -  Be able to accurately and reliably report symptoms (including treatment-emergent&#xD;
                  signs and symptoms).&#xD;
&#xD;
               -  Take study drug as required by protocol.&#xD;
&#xD;
          9. Be on stable glycemic control with standard of care diabetic therapies (â‰¥3 months&#xD;
             prior to screening). This includes diet and exercise alone or in association with oral&#xD;
             or injectable anti-diabetic drugs (monotherapy or combinations) that are not&#xD;
             anticipated to change during the course of the study, except if medically required.&#xD;
&#xD;
         10. Be on stable nonpharmacological pain treatment for at least 4 weeks prior to screening&#xD;
             and remain on this stable treatment throughout the study (unless otherwise directed by&#xD;
             a physician). Nonpharmacologic pain treatment includes the following:&#xD;
             relaxation/hypnosis, physical or occupational therapy, counseling, etc. Episodic or&#xD;
             periodic treatments, such as monthly injections for treatment of pain (e.g. local&#xD;
             anesthetics) or trans electrical nerve stimulation will not be permitted.&#xD;
&#xD;
         11. Regular and stable use of pharmacological pain treatment (less than or equal to 30 mg&#xD;
             morphine equivalent) for at least 8 weeks prior to screening.&#xD;
&#xD;
         12. General health status must be acceptable for participation in this 12-week clinical&#xD;
             study, with no hospitalizations for medical conditions within 12 weeks before and&#xD;
             during screening per judgment of the Investigator. Any question regarding eligibility&#xD;
             will be addressed with the medical monitor.&#xD;
&#xD;
         13. Fluency (oral and written) in the language in which the standardized tests will be&#xD;
             administered.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria will be excluded from&#xD;
        participating in the study:&#xD;
&#xD;
          1. Severe neuropathy as determined by a UENS score &gt; 24 at screening&#xD;
&#xD;
          2. Proliferative retinopathy or maculopathy requiring acute treatment.&#xD;
&#xD;
          3. Requiring dialysis.&#xD;
&#xD;
          4. Impaired liver function, defined as aspartate aminotransferase or alanine&#xD;
             aminotransferase &gt; 3 times the upper limit of normal.&#xD;
&#xD;
          5. Presence of clinically significant peripheral or autonomic neuropathy that is clearly&#xD;
             of nondiabetic origin.&#xD;
&#xD;
          6. Prior week VAS for pain and/or altered sensations on lower extremities &lt; 30 mm (0 mm =&#xD;
             no pain-100 mm = very severe pain) at screening.&#xD;
&#xD;
          7. Local (topical) anesthetics or analgesics including lidocaine, capsaicin, cannabinoid&#xD;
             (CBD) oil/products or compounded topical pharmaceutical agents.&#xD;
&#xD;
          8. Uncontrolled treated/untreated hypertension (systolic blood pressure [BP] &gt; 180 or&#xD;
             diastolic BP &gt; 100 at screening).&#xD;
&#xD;
          9. Amputations of lower extremities or presence of foot ulcers.&#xD;
&#xD;
         10. Clinically significant active macrovascular disease, including myocardial infarction&#xD;
             or cerebrovascular event within the past 6 months.&#xD;
&#xD;
         11. Uncontrolled or untreated hypothyroidism.&#xD;
&#xD;
         12. Active and/or systemic infections (e.g., HIV, hepatitis, tuberculosis, syphilis), or a&#xD;
             history of severe infection during the 30 days prior to screening.&#xD;
&#xD;
         13. Evidence of severely immunocompromised status.&#xD;
&#xD;
         14. Major surgical procedure during the 90 days prior to screening.&#xD;
&#xD;
         15. Diagnosis and/or treatment of malignancy (except for basal cell or squamous cell skin&#xD;
             cancer, in-situ carcinoma of the cervix, or in-situ prostate cancer) within the past 5&#xD;
             years.&#xD;
&#xD;
         16. Clinically significant gastric emptying abnormality (e.g., severe gastroparesis).&#xD;
&#xD;
         17. Urinary retention or an enlarged prostate.&#xD;
&#xD;
         18. Uncontrolled glaucoma.&#xD;
&#xD;
         19. Other clinically significant, active (over the past 12 months) disease of the&#xD;
             gastrointestinal, pulmonary, neurological, genitourinary, endocrine, rheumatologic or&#xD;
             hematological system that, in the opinion of the Investigator, would compromise the&#xD;
             subject's participation in the study, might confound the results of the study, or pose&#xD;
             additional risk in administering the study drug.&#xD;
&#xD;
         20. New treatment with (&lt; 3 months) vitamins and supplements at the discretion of the PI.&#xD;
&#xD;
         21. Known or suspected history of alcohol or substance abuse (a stable and regular use of&#xD;
             medical marijuana is acceptable).&#xD;
&#xD;
         22. Mental incapacity, unwillingness, or language barrier precluding adequate&#xD;
             understanding of or cooperation with the study.&#xD;
&#xD;
         23. Women of childbearing potential who are pregnant, breast-feeding, or intend to become&#xD;
             pregnant. Women of childbearing potential must have a negative pregnancy test at&#xD;
             screening and must agree to use adequate contraceptive methods during the study and&#xD;
             for 1 additional menstrual cycle following the end-of treatment visit (see inclusion&#xD;
             criterion 5).&#xD;
&#xD;
         24. History of allergy or sensitivity to anticholinergics or any of the components of the&#xD;
             investigational product formulations.&#xD;
&#xD;
         25. Known allergy or hypersensitivity to pirenzepine or another component of the&#xD;
             investigational product.&#xD;
&#xD;
         26. History of sensitive skin, as defined by a requirement to use soap and skin products&#xD;
             formulated for &quot;sensitive skin,&quot; as determined by the Investigator.&#xD;
&#xD;
         27. Currently taking any medicines to treat overactive bladder (anticholinergic agents,&#xD;
             such as Gelnique), or antispasmodics.&#xD;
&#xD;
         28. Failure or inability to perform screening or baseline assessments.&#xD;
&#xD;
         29. Patients with any condition that could potentially interfere with the conduct of the&#xD;
             study or confound efficacy evaluations, including the following as specified in&#xD;
             numbers 30 through 36 below:&#xD;
&#xD;
         30. Pain or neuropathy from another cause (including central pain, radiculopathy, painful&#xD;
             arthritis, autoimmune and inflammatory diseases including rheumatoid arthritis, lupus,&#xD;
             Sjogren's syndrome, vasculitic disorders such as periarteritis nodosa, Churg-Strauss,&#xD;
             etc., celiac disease, Crohn's disease, ulcerative colitis, spondyloarthropathies,&#xD;
             sarcoidosis, etc.) at the discretion of the PI.&#xD;
&#xD;
         31. Skin or soft-tissue lesions in the dosing area (calves, ankles and tops of feet)&#xD;
             affected by neuropathy that are painful or could alter sensation.&#xD;
&#xD;
         32. Exposure to an experimental drug, experimental biologic, or experimental medical&#xD;
             device within 3 months before screening.&#xD;
&#xD;
         33. Any open wound(s) and/or sunburn(s) in the dosing area. Subjects who have a wound&#xD;
             and/or sunburn at screening that is anticipated to resolve before day -1 can be&#xD;
             enrolled.&#xD;
&#xD;
         34. History of a serious skin disease (as determined by the Investigator), such as skin&#xD;
             cancer, psoriasis, stasis dermatitis or eczema.&#xD;
&#xD;
         35. Receipt of a tattoo in the dosing area within 12 months of dosing.&#xD;
&#xD;
         36. Known or untreated Lyme disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Hansen</last_name>
    <role>Study Director</role>
    <affiliation>WinSanTor, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Hansen</last_name>
    <phone>858-848-4831</phone>
    <email>ahansen@winsantor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stan Kim</last_name>
    <phone>858.336.8094</phone>
    <email>skim@winsantor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510-1001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Ingram</last_name>
      <phone>757-446-8485</phone>
      <email>ingramam@evms.edu</email>
    </contact>
    <investigator>
      <last_name>Elias Siraj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolina Casellini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 2 DM</keyword>
  <keyword>US</keyword>
  <keyword>WST-057</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirenzepine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

